Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo. This report characterises the longer-term safety and efficacy of sotatercept in the PULSAR open-label extension. We...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The European respiratory journal 2023-01, Vol.61 (1), p.2201347
Hauptverfasser:	Humbert, Marc, McLaughlin, Vallerie, Gibbs, J Simon R, Gomberg-Maitland, Mardi, Hoeper, Marius M, Preston, Ioana R, Souza, Rogerio, Waxman, Aaron B, Ghofrani, Hossein-Ardeschir, Escribano Subias, Pilar, Feldman, Jeremy, Meyer, Gisela, Montani, David, Olsson, Karen M, Manimaran, Solaiappan, de Oliveira Pena, Janethe, Badesch, David B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult DEAE-Dextran Double-Blind Method Familial Primary Pulmonary Hypertension Humans Life Sciences Original s Pulmonary Arterial Hypertension Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!